{"gene":"PDE12","run_date":"2026-04-29T11:37:58","timeline":{"discoveries":[{"year":2011,"finding":"PDE12 is a mitochondrial-localized poly(A)-specific exoribonuclease that removes poly(A) extensions from mitochondrial mRNAs both in vitro and in intact mitochondria of cultured cells, and excess PDE12 causes severe inhibition of mitochondrial protein synthesis and respiratory incompetence in a transcript-dependent manner.","method":"In vitro deadenylation assay, overexpression in cultured cells with mitochondrial fractionation, mitochondrial translation assay, respiratory function measurement","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro enzymatic assay combined with cellular localization, translation, and respiration readouts; replicated in vitro and in vivo in cells","pmids":["21666256"],"is_preprint":false},{"year":2015,"finding":"PDE12 degrades 2',5'-oligoadenylate (2-5A), the second messenger that activates RNase-L in the OAS/RNase-L innate immune antiviral pathway; PDE12-null cells show elevated 2-5A levels after IFN or poly(I-C) treatment and are resistant to encephalomyocarditis virus, rhinovirus, and RSV. Crystal structure of PDE12 bound to an inhibitor was solved.","method":"TALEN-mediated PDE12 knockout cell line, 2-5A level measurement, viral resistance assays, crystal structure determination, DNA-encoded chemical library screening for inhibitors","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — genetic KO with defined molecular and antiviral phenotype, crystal structure, multiple orthogonal methods in one study","pmids":["26055709"],"is_preprint":false},{"year":2024,"finding":"Bi-allelic missense variants in PDE12 cause accumulation of spuriously polyadenylated mitochondrial RNAs (detected by MPAT-Seq), mitochondrial respiratory chain deficiencies (COX deficiency in muscle), and neonatal disease, confirming PDE12's essential role in mitochondrial RNA quality control by pruning aberrant poly(A) tails from mitochondrial non-coding RNAs.","method":"Whole exome sequencing of affected families, patient-derived fibroblast analysis, mitochondrial poly(A)-tail RNA sequencing (MPAT-Seq), protein level quantification","journal":"EMBO molecular medicine","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (WES, MPAT-Seq, biochemical) across three unrelated families, consistent with prior mechanistic work","pmids":["39567835"],"is_preprint":false},{"year":2024,"finding":"PDE12 localizes to mitochondria and its overexpression disrupts oxidative phosphorylation (OXPHOS) complexes, impairs mitochondrial membrane potential, increases mitochondrial ROS, and causes epithelial-mesenchymal transition and tight junction disruption; knockdown of PDE12 rescues arecoline-induced mitochondrial dysfunction and epithelial barrier dysfunction.","method":"PDE12 plasmid overexpression and siRNA knockdown in HOK cells, mitochondrial fractionation, OXPHOS complex measurement, mitochondrial membrane potential assay, mtROS measurement, transepithelial electrical resistance, western blotting","journal":"European journal of pharmacology","confidence":"Medium","confidence_rationale":"Tier 2–3 — KD/OE with defined mitochondrial phenotypes, single lab, multiple readouts but no reconstitution or structure","pmids":["38325798"],"is_preprint":false},{"year":2026,"finding":"The transcription factor EGR1 binds directly to the PDE12 gene promoter and upregulates PDE12 expression; EGR1-driven PDE12 overexpression mediates mitochondrial dysfunction and oral mucosal epithelial barrier damage, as demonstrated by the rescue of these phenotypes upon EGR1 silencing even with forced PDE12 overexpression.","method":"Electrophoretic mobility shift assay (EMSA), chromatin immunoprecipitation (ChIP), EGR1 siRNA silencing combined with PDE12 overexpression, mitochondrial functional assays","journal":"European journal of pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — EMSA and ChIP directly demonstrate EGR1–PDE12 promoter interaction; genetic rescue experiment places EGR1 upstream of PDE12; single lab","pmids":["42000021"],"is_preprint":false}],"current_model":"PDE12 is a mitochondria-localized poly(A)-specific exoribonuclease that removes spurious poly(A) tails from mitochondrial RNAs to maintain proper RNA processing and translation; it also degrades the 2',5'-oligoadenylate (2-5A) second messenger to negatively regulate the OAS/RNase-L innate immune antiviral pathway, and its expression is transcriptionally controlled by EGR1; loss-of-function causes accumulation of aberrantly polyadenylated mt-RNAs, respiratory chain deficiency, and severe neonatal disease."},"narrative":{"teleology":[{"year":2011,"claim":"Establishing that PDE12 is a mitochondrial poly(A)-specific exoribonuclease answered the fundamental question of what enzyme trims poly(A) tails from mitochondrial mRNAs and revealed that its overexpression inhibits mitochondrial translation and respiration.","evidence":"In vitro deadenylation assays, mitochondrial fractionation, translation assays, and respiratory function measurements in cultured cells","pmids":["21666256"],"confidence":"High","gaps":["No identification of how PDE12 activity is regulated in vivo","Substrate specificity across all mitochondrial RNA species not fully mapped","No structural information on enzyme–substrate interaction"]},{"year":2015,"claim":"Demonstrating that PDE12 degrades 2-5A and that its loss enhances antiviral resistance established a second, cytosolic function as a negative regulator of the OAS/RNase L innate immune pathway, broadening PDE12's role beyond mitochondrial RNA metabolism.","evidence":"TALEN-mediated PDE12 knockout cells, 2-5A quantification, viral resistance assays against EMCV/rhinovirus/RSV, crystal structure of PDE12 with an inhibitor","pmids":["26055709"],"confidence":"High","gaps":["How PDE12 partitions between mitochondrial and cytosolic/2-5A degradation pools is unknown","Relative physiological importance of the 2-5A degradation versus mitochondrial poly(A) trimming functions not resolved","No in vivo animal model validation of antiviral phenotype"]},{"year":2024,"claim":"Discovery that bi-allelic PDE12 mutations cause neonatal disease with aberrantly polyadenylated mitochondrial RNAs and COX deficiency established PDE12 as essential for human mitochondrial RNA quality control and linked it to a Mendelian respiratory chain disorder.","evidence":"Whole exome sequencing in three unrelated families, MPAT-Seq of patient fibroblasts, mitochondrial respiratory chain enzymology","pmids":["39567835"],"confidence":"High","gaps":["Precise mechanism by which aberrant polyadenylation of non-coding mt-RNAs disrupts OXPHOS not delineated","No rescue experiment with wild-type PDE12 in patient cells reported","Genotype–phenotype spectrum across different PDE12 variants remains limited to a few families"]},{"year":2024,"claim":"Showing that PDE12 overexpression disrupts OXPHOS complexes, membrane potential, and epithelial tight junctions — and that knockdown rescues these phenotypes — connected excessive PDE12 activity to mitochondrial ROS generation and epithelial-mesenchymal transition.","evidence":"PDE12 overexpression and siRNA knockdown in HOK cells with OXPHOS complex quantification, membrane potential assays, mtROS measurement, and transepithelial electrical resistance","pmids":["38325798"],"confidence":"Medium","gaps":["Single cell type (oral keratinocyte); generalizability to other epithelia not tested","Whether EMT is a direct consequence of PDE12-driven mitochondrial dysfunction or a secondary effect is unclear","No identification of specific mt-RNA substrates mediating the OXPHOS disruption upon overexpression"]},{"year":2026,"claim":"Identification of EGR1 as a direct transcriptional activator of PDE12 answered how PDE12 expression is upregulated, placing it downstream of a stress-responsive transcription factor.","evidence":"EMSA and ChIP demonstrating EGR1 binding to PDE12 promoter; EGR1 silencing rescues PDE12-overexpression-driven mitochondrial dysfunction","pmids":["42000021"],"confidence":"Medium","gaps":["Whether EGR1 is the sole or primary transcriptional regulator of PDE12 is not established","Physiological signals upstream of EGR1 that drive PDE12 upregulation beyond arecoline exposure are unknown","Single lab finding; independent replication in other systems not yet reported"]},{"year":null,"claim":"How PDE12 partitions between its mitochondrial poly(A) trimming and cytosolic 2-5A degradation functions, and what governs substrate selection among different mitochondrial RNA species, remain unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No dual-localization trafficking mechanism elucidated","No structural model of PDE12 engaged with a mitochondrial RNA substrate","Relative contribution of the two functions to human disease phenotypes unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[0,1,2]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,1]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[0,2,3]}],"pathway":[{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[0,2]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[1]}],"complexes":[],"partners":["EGR1"],"other_free_text":[]},"mechanistic_narrative":"PDE12 is a mitochondria-localized poly(A)-specific exoribonuclease that maintains mitochondrial RNA integrity and also functions as a negative regulator of the OAS/RNase L innate immune pathway. Within mitochondria, PDE12 removes spurious poly(A) extensions from mitochondrial mRNAs and non-coding RNAs; excess PDE12 severely inhibits mitochondrial protein synthesis and disrupts oxidative phosphorylation, while loss-of-function leads to accumulation of aberrantly polyadenylated mitochondrial RNAs, respiratory chain deficiency, and neonatal disease in humans [PMID:21666256, PMID:39567835, PMID:38325798]. PDE12 also degrades 2',5'-oligoadenylate (2-5A), and PDE12-null cells exhibit elevated 2-5A levels and enhanced resistance to encephalomyocarditis virus, rhinovirus, and RSV [PMID:26055709]. Transcription of PDE12 is directly upregulated by EGR1 binding to its promoter [PMID:42000021]."},"prefetch_data":{"uniprot":{"accession":"Q6L8Q7","full_name":"2',5'-phosphodiesterase 12","aliases":["Mitochondrial deadenylase"],"length_aa":609,"mass_kda":67.4,"function":"Enzyme that cleaves 2',5'-phosphodiester bond linking adenosines of the 5'-triphosphorylated oligoadenylates, triphosphorylated oligoadenylates referred as 2-5A modulates the 2-5A system. Degrades triphosphorylated 2-5A to produce AMP and ATP (PubMed:26055709). Also cleaves 3',5'-phosphodiester bond of oligoadenylates (PubMed:21666256, PubMed:26055709, PubMed:30389976). Plays a role as a negative regulator of the 2-5A system that is one of the major pathways for antiviral and antitumor functions induced by interferons (IFNs). Suppression of this enzyme increases cellular 2-5A levels and decreases viral replication in cultured small-airway epithelial cells and Hela cells (PubMed:26055709)","subcellular_location":"Mitochondrion matrix","url":"https://www.uniprot.org/uniprotkb/Q6L8Q7/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PDE12","classification":"Not Classified","n_dependent_lines":321,"n_total_lines":1208,"dependency_fraction":0.26572847682119205},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PDE12","total_profiled":1310},"omim":[{"mim_id":"616519","title":"PHOSPHODIESTERASE 12; PDE12","url":"https://www.omim.org/entry/616519"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/PDE12"},"hgnc":{"alias_symbol":["DKFZp667B1218","2'-PDE","3635"],"prev_symbol":[]},"alphafold":{"accession":"Q6L8Q7","domains":[{"cath_id":"3.10.20","chopping":"36-84_123-161","consensus_level":"medium","plddt":91.3885,"start":36,"end":161},{"cath_id":"2.60.40.2700","chopping":"164-273","consensus_level":"high","plddt":93.0471,"start":164,"end":273},{"cath_id":"3.60.10.10","chopping":"279-609","consensus_level":"medium","plddt":98.0665,"start":279,"end":609}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q6L8Q7","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q6L8Q7-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q6L8Q7-F1-predicted_aligned_error_v6.png","plddt_mean":89.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PDE12","jax_strain_url":"https://www.jax.org/strain/search?query=PDE12"},"sequence":{"accession":"Q6L8Q7","fasta_url":"https://rest.uniprot.org/uniprotkb/Q6L8Q7.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q6L8Q7/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q6L8Q7"}},"corpus_meta":[{"pmid":"11562475","id":"PMC_11562475","title":"Cysteine-3635 is responsible for skeletal muscle ryanodine receptor modulation by NO.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11562475","citation_count":252,"is_preprint":false},{"pmid":"21666256","id":"PMC_21666256","title":"PDE12 removes mitochondrial RNA poly(A) tails and controls translation in human mitochondria.","date":"2011","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/21666256","citation_count":89,"is_preprint":false},{"pmid":"10601232","id":"PMC_10601232","title":"A role for cysteine 3635 of RYR1 in redox modulation and calmodulin binding.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10601232","citation_count":63,"is_preprint":false},{"pmid":"26055709","id":"PMC_26055709","title":"The Role of Phosphodiesterase 12 (PDE12) as a Negative Regulator of the Innate Immune Response and the Discovery of Antiviral Inhibitors.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26055709","citation_count":61,"is_preprint":false},{"pmid":"2401310","id":"PMC_2401310","title":"Protective effects of KW-3635, a novel thromboxane A2 antagonist, in murine traumatic shock.","date":"1990","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/2401310","citation_count":14,"is_preprint":false},{"pmid":"7967232","id":"PMC_7967232","title":"Antithrombotic effects of KW-3635, a thromboxane A2-receptor antagonist, in guinea pigs.","date":"1994","source":"Japanese journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/7967232","citation_count":13,"is_preprint":false},{"pmid":"38325798","id":"PMC_38325798","title":"PDE12 disrupts mitochondrial oxidative phosphorylation and mediates mitochondrial dysfunction to induce oral mucosal epithelial barrier damage in oral submucous fibrosis.","date":"2024","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38325798","citation_count":6,"is_preprint":false},{"pmid":"8250642","id":"PMC_8250642","title":"The novel thromboxane A2 receptor antagonist KW-3635 reduces infarct size in a canine model of coronary occlusion and reperfusion.","date":"1993","source":"Archives internationales de pharmacodynamie et de therapie","url":"https://pubmed.ncbi.nlm.nih.gov/8250642","citation_count":6,"is_preprint":false},{"pmid":"1387741","id":"PMC_1387741","title":"Characterization of thromboxane A2/prostaglandin H2 receptors in porcine coronary artery--the inhibitory effect of a novel dibenzoxepin derivative, KW-3635.","date":"1992","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/1387741","citation_count":5,"is_preprint":false},{"pmid":"36307540","id":"PMC_36307540","title":"PDE12 in type 1 diabetes.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/36307540","citation_count":4,"is_preprint":false},{"pmid":"8121078","id":"PMC_8121078","title":"Effects of KW-3635, a specific thromboxane A2-receptor antagonist, on the development of lupus nephritis in NZB x NZW F1 mice.","date":"1993","source":"Japanese journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/8121078","citation_count":4,"is_preprint":false},{"pmid":"8121085","id":"PMC_8121085","title":"Inhibitory effect of KW-3635, a new thromboxane A2-receptor antagonist, on arterial thrombosis in guinea pigs.","date":"1993","source":"Japanese journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/8121085","citation_count":3,"is_preprint":false},{"pmid":"8089929","id":"PMC_8089929","title":"Protective effects of KW-3635, a thromboxane A2 antagonist, on arachidonic acid-induced transient cerebral ischemia in dogs.","date":"1994","source":"Japanese journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/8089929","citation_count":2,"is_preprint":false},{"pmid":"39567835","id":"PMC_39567835","title":"Pathogenic PDE12 variants impair mitochondrial RNA processing causing neonatal mitochondrial disease.","date":"2024","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39567835","citation_count":1,"is_preprint":false},{"pmid":"7967228","id":"PMC_7967228","title":"Protective effect of KW-3635, a specific thromboxane A2-receptor antagonist, on experimental glomerulonephritis in mice.","date":"1994","source":"Japanese journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/7967228","citation_count":1,"is_preprint":false},{"pmid":"39567836","id":"PMC_39567836","title":"PDE12 mediated pruning of the poly-A tail of mitochondrial DNA-encoded tRNAs is essential for survival.","date":"2024","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39567836","citation_count":0,"is_preprint":false},{"pmid":"8444379","id":"PMC_8444379","title":"[Effects of KW-3635 on the diuretic action of furosemide in rats].","date":"1993","source":"Nihon yakurigaku zasshi. Folia pharmacologica Japonica","url":"https://pubmed.ncbi.nlm.nih.gov/8444379","citation_count":0,"is_preprint":false},{"pmid":"8000373","id":"PMC_8000373","title":"The novel thromboxane A2 receptor antagonist KW-3635 abolishes the cyclic flow reduction in the canine carotid artery.","date":"1994","source":"Biological & pharmaceutical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/8000373","citation_count":0,"is_preprint":false},{"pmid":"42000021","id":"PMC_42000021","title":"EGR1 regulates PDE12 mediated mitochondrial dysfunction to induce oral mucosal epithelial barrier damage in oral submucous fibrosis.","date":"2026","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/42000021","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":9630,"output_tokens":1445,"usd":0.025282},"stage2":{"model":"claude-opus-4-6","input_tokens":4670,"output_tokens":3663,"usd":0.172387},"total_usd":0.197669,"stage1_batch_id":"msgbatch_012ZiiCUBfB62NCTQd4Bk1Jo","stage2_batch_id":"msgbatch_01Xuqq9aUHoQouS7UVGZNStZ","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2011,\n      \"finding\": \"PDE12 is a mitochondrial-localized poly(A)-specific exoribonuclease that removes poly(A) extensions from mitochondrial mRNAs both in vitro and in intact mitochondria of cultured cells, and excess PDE12 causes severe inhibition of mitochondrial protein synthesis and respiratory incompetence in a transcript-dependent manner.\",\n      \"method\": \"In vitro deadenylation assay, overexpression in cultured cells with mitochondrial fractionation, mitochondrial translation assay, respiratory function measurement\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro enzymatic assay combined with cellular localization, translation, and respiration readouts; replicated in vitro and in vivo in cells\",\n      \"pmids\": [\"21666256\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PDE12 degrades 2',5'-oligoadenylate (2-5A), the second messenger that activates RNase-L in the OAS/RNase-L innate immune antiviral pathway; PDE12-null cells show elevated 2-5A levels after IFN or poly(I-C) treatment and are resistant to encephalomyocarditis virus, rhinovirus, and RSV. Crystal structure of PDE12 bound to an inhibitor was solved.\",\n      \"method\": \"TALEN-mediated PDE12 knockout cell line, 2-5A level measurement, viral resistance assays, crystal structure determination, DNA-encoded chemical library screening for inhibitors\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genetic KO with defined molecular and antiviral phenotype, crystal structure, multiple orthogonal methods in one study\",\n      \"pmids\": [\"26055709\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Bi-allelic missense variants in PDE12 cause accumulation of spuriously polyadenylated mitochondrial RNAs (detected by MPAT-Seq), mitochondrial respiratory chain deficiencies (COX deficiency in muscle), and neonatal disease, confirming PDE12's essential role in mitochondrial RNA quality control by pruning aberrant poly(A) tails from mitochondrial non-coding RNAs.\",\n      \"method\": \"Whole exome sequencing of affected families, patient-derived fibroblast analysis, mitochondrial poly(A)-tail RNA sequencing (MPAT-Seq), protein level quantification\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (WES, MPAT-Seq, biochemical) across three unrelated families, consistent with prior mechanistic work\",\n      \"pmids\": [\"39567835\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PDE12 localizes to mitochondria and its overexpression disrupts oxidative phosphorylation (OXPHOS) complexes, impairs mitochondrial membrane potential, increases mitochondrial ROS, and causes epithelial-mesenchymal transition and tight junction disruption; knockdown of PDE12 rescues arecoline-induced mitochondrial dysfunction and epithelial barrier dysfunction.\",\n      \"method\": \"PDE12 plasmid overexpression and siRNA knockdown in HOK cells, mitochondrial fractionation, OXPHOS complex measurement, mitochondrial membrane potential assay, mtROS measurement, transepithelial electrical resistance, western blotting\",\n      \"journal\": \"European journal of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — KD/OE with defined mitochondrial phenotypes, single lab, multiple readouts but no reconstitution or structure\",\n      \"pmids\": [\"38325798\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"The transcription factor EGR1 binds directly to the PDE12 gene promoter and upregulates PDE12 expression; EGR1-driven PDE12 overexpression mediates mitochondrial dysfunction and oral mucosal epithelial barrier damage, as demonstrated by the rescue of these phenotypes upon EGR1 silencing even with forced PDE12 overexpression.\",\n      \"method\": \"Electrophoretic mobility shift assay (EMSA), chromatin immunoprecipitation (ChIP), EGR1 siRNA silencing combined with PDE12 overexpression, mitochondrial functional assays\",\n      \"journal\": \"European journal of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — EMSA and ChIP directly demonstrate EGR1–PDE12 promoter interaction; genetic rescue experiment places EGR1 upstream of PDE12; single lab\",\n      \"pmids\": [\"42000021\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PDE12 is a mitochondria-localized poly(A)-specific exoribonuclease that removes spurious poly(A) tails from mitochondrial RNAs to maintain proper RNA processing and translation; it also degrades the 2',5'-oligoadenylate (2-5A) second messenger to negatively regulate the OAS/RNase-L innate immune antiviral pathway, and its expression is transcriptionally controlled by EGR1; loss-of-function causes accumulation of aberrantly polyadenylated mt-RNAs, respiratory chain deficiency, and severe neonatal disease.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"PDE12 is a mitochondria-localized poly(A)-specific exoribonuclease that maintains mitochondrial RNA integrity and also functions as a negative regulator of the OAS/RNase L innate immune pathway. Within mitochondria, PDE12 removes spurious poly(A) extensions from mitochondrial mRNAs and non-coding RNAs; excess PDE12 severely inhibits mitochondrial protein synthesis and disrupts oxidative phosphorylation, while loss-of-function leads to accumulation of aberrantly polyadenylated mitochondrial RNAs, respiratory chain deficiency, and neonatal disease in humans [PMID:21666256, PMID:39567835, PMID:38325798]. PDE12 also degrades 2',5'-oligoadenylate (2-5A), and PDE12-null cells exhibit elevated 2-5A levels and enhanced resistance to encephalomyocarditis virus, rhinovirus, and RSV [PMID:26055709]. Transcription of PDE12 is directly upregulated by EGR1 binding to its promoter [PMID:42000021].\",\n  \"teleology\": [\n    {\n      \"year\": 2011,\n      \"claim\": \"Establishing that PDE12 is a mitochondrial poly(A)-specific exoribonuclease answered the fundamental question of what enzyme trims poly(A) tails from mitochondrial mRNAs and revealed that its overexpression inhibits mitochondrial translation and respiration.\",\n      \"evidence\": \"In vitro deadenylation assays, mitochondrial fractionation, translation assays, and respiratory function measurements in cultured cells\",\n      \"pmids\": [\"21666256\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No identification of how PDE12 activity is regulated in vivo\",\n        \"Substrate specificity across all mitochondrial RNA species not fully mapped\",\n        \"No structural information on enzyme–substrate interaction\"\n      ]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrating that PDE12 degrades 2-5A and that its loss enhances antiviral resistance established a second, cytosolic function as a negative regulator of the OAS/RNase L innate immune pathway, broadening PDE12's role beyond mitochondrial RNA metabolism.\",\n      \"evidence\": \"TALEN-mediated PDE12 knockout cells, 2-5A quantification, viral resistance assays against EMCV/rhinovirus/RSV, crystal structure of PDE12 with an inhibitor\",\n      \"pmids\": [\"26055709\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"How PDE12 partitions between mitochondrial and cytosolic/2-5A degradation pools is unknown\",\n        \"Relative physiological importance of the 2-5A degradation versus mitochondrial poly(A) trimming functions not resolved\",\n        \"No in vivo animal model validation of antiviral phenotype\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Discovery that bi-allelic PDE12 mutations cause neonatal disease with aberrantly polyadenylated mitochondrial RNAs and COX deficiency established PDE12 as essential for human mitochondrial RNA quality control and linked it to a Mendelian respiratory chain disorder.\",\n      \"evidence\": \"Whole exome sequencing in three unrelated families, MPAT-Seq of patient fibroblasts, mitochondrial respiratory chain enzymology\",\n      \"pmids\": [\"39567835\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Precise mechanism by which aberrant polyadenylation of non-coding mt-RNAs disrupts OXPHOS not delineated\",\n        \"No rescue experiment with wild-type PDE12 in patient cells reported\",\n        \"Genotype–phenotype spectrum across different PDE12 variants remains limited to a few families\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showing that PDE12 overexpression disrupts OXPHOS complexes, membrane potential, and epithelial tight junctions — and that knockdown rescues these phenotypes — connected excessive PDE12 activity to mitochondrial ROS generation and epithelial-mesenchymal transition.\",\n      \"evidence\": \"PDE12 overexpression and siRNA knockdown in HOK cells with OXPHOS complex quantification, membrane potential assays, mtROS measurement, and transepithelial electrical resistance\",\n      \"pmids\": [\"38325798\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single cell type (oral keratinocyte); generalizability to other epithelia not tested\",\n        \"Whether EMT is a direct consequence of PDE12-driven mitochondrial dysfunction or a secondary effect is unclear\",\n        \"No identification of specific mt-RNA substrates mediating the OXPHOS disruption upon overexpression\"\n      ]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Identification of EGR1 as a direct transcriptional activator of PDE12 answered how PDE12 expression is upregulated, placing it downstream of a stress-responsive transcription factor.\",\n      \"evidence\": \"EMSA and ChIP demonstrating EGR1 binding to PDE12 promoter; EGR1 silencing rescues PDE12-overexpression-driven mitochondrial dysfunction\",\n      \"pmids\": [\"42000021\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether EGR1 is the sole or primary transcriptional regulator of PDE12 is not established\",\n        \"Physiological signals upstream of EGR1 that drive PDE12 upregulation beyond arecoline exposure are unknown\",\n        \"Single lab finding; independent replication in other systems not yet reported\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How PDE12 partitions between its mitochondrial poly(A) trimming and cytosolic 2-5A degradation functions, and what governs substrate selection among different mitochondrial RNA species, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No dual-localization trafficking mechanism elucidated\",\n        \"No structural model of PDE12 engaged with a mitochondrial RNA substrate\",\n        \"Relative contribution of the two functions to human disease phenotypes unknown\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [0, 1, 2]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 2, 3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [0, 2]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"EGR1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\nWait, I made an error in pathway — I accidentally included a GO term. Let me fix that.\n\n```json\n{\n  \"mechanistic_narrative\": \"PDE12 is a mitochondria-localized poly(A)-specific exoribonuclease that maintains mitochondrial RNA integrity and also functions as a negative regulator of the OAS/RNase L innate immune pathway. Within mitochondria, PDE12 removes spurious poly(A) extensions from mitochondrial mRNAs and non-coding RNAs; excess PDE12 severely inhibits mitochondrial protein synthesis and disrupts oxidative phosphorylation, while loss-of-function leads to accumulation of aberrantly polyadenylated mitochondrial RNAs, respiratory chain deficiency, and neonatal disease in humans [PMID:21666256, PMID:39567835, PMID:38325798]. PDE12 also degrades 2',5'-oligoadenylate (2-5A), and PDE12-null cells exhibit elevated 2-5A levels and enhanced resistance to encephalomyocarditis virus, rhinovirus, and RSV [PMID:26055709]. Transcription of PDE12 is directly upregulated by EGR1 binding to its promoter [PMID:42000021].\",\n  \"teleology\": [\n    {\n      \"year\": 2011,\n      \"claim\": \"Establishing that PDE12 is a mitochondrial poly(A)-specific exoribonuclease answered the fundamental question of what enzyme trims poly(A) tails from mitochondrial mRNAs and revealed that its overexpression inhibits mitochondrial translation and respiration.\",\n      \"evidence\": \"In vitro deadenylation assays, mitochondrial fractionation, translation assays, and respiratory function measurements in cultured cells\",\n      \"pmids\": [\"21666256\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No identification of how PDE12 activity is regulated in vivo\",\n        \"Substrate specificity across all mitochondrial RNA species not fully mapped\",\n        \"No structural information on enzyme–substrate interaction\"\n      ]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrating that PDE12 degrades 2-5A and that its loss enhances antiviral resistance established a second, cytosolic function as a negative regulator of the OAS/RNase L innate immune pathway, broadening PDE12's role beyond mitochondrial RNA metabolism.\",\n      \"evidence\": \"TALEN-mediated PDE12 knockout cells, 2-5A quantification, viral resistance assays against EMCV/rhinovirus/RSV, crystal structure of PDE12 with an inhibitor\",\n      \"pmids\": [\"26055709\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"How PDE12 partitions between mitochondrial and cytosolic/2-5A degradation pools is unknown\",\n        \"Relative physiological importance of the 2-5A degradation versus mitochondrial poly(A) trimming functions not resolved\",\n        \"No in vivo animal model validation of antiviral phenotype\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Discovery that bi-allelic PDE12 mutations cause neonatal disease with aberrantly polyadenylated mitochondrial RNAs and COX deficiency established PDE12 as essential for human mitochondrial RNA quality control and linked it to a Mendelian respiratory chain disorder.\",\n      \"evidence\": \"Whole exome sequencing in three unrelated families, MPAT-Seq of patient fibroblasts, mitochondrial respiratory chain enzymology\",\n      \"pmids\": [\"39567835\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Precise mechanism by which aberrant polyadenylation of non-coding mt-RNAs disrupts OXPHOS not delineated\",\n        \"No rescue experiment with wild-type PDE12 in patient cells reported\",\n        \"Genotype–phenotype spectrum across different PDE12 variants remains limited to a few families\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showing that PDE12 overexpression disrupts OXPHOS complexes, membrane potential, and epithelial tight junctions — and that knockdown rescues these phenotypes — connected excessive PDE12 activity to mitochondrial ROS generation and epithelial-mesenchymal transition.\",\n      \"evidence\": \"PDE12 overexpression and siRNA knockdown in HOK cells with OXPHOS complex quantification, membrane potential assays, mtROS measurement, and transepithelial electrical resistance\",\n      \"pmids\": [\"38325798\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single cell type (oral keratinocyte); generalizability to other epithelia not tested\",\n        \"Whether EMT is a direct consequence of PDE12-driven mitochondrial dysfunction or a secondary effect is unclear\",\n        \"No identification of specific mt-RNA substrates mediating the OXPHOS disruption upon overexpression\"\n      ]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Identification of EGR1 as a direct transcriptional activator of PDE12 answered how PDE12 expression is upregulated, placing it downstream of a stress-responsive transcription factor.\",\n      \"evidence\": \"EMSA and ChIP demonstrating EGR1 binding to PDE12 promoter; EGR1 silencing rescues PDE12-overexpression-driven mitochondrial dysfunction\",\n      \"pmids\": [\"42000021\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether EGR1 is the sole or primary transcriptional regulator of PDE12 is not established\",\n        \"Physiological signals upstream of EGR1 that drive PDE12 upregulation beyond arecoline exposure are unknown\",\n        \"Single lab finding; independent replication in other systems not yet reported\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How PDE12 partitions between its mitochondrial poly(A) trimming and cytosolic 2-5A degradation functions, and what governs substrate selection among different mitochondrial RNA species, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No dual-localization trafficking mechanism elucidated\",\n        \"No structural model of PDE12 engaged with a mitochondrial RNA substrate\",\n        \"Relative contribution of the two functions to human disease phenotypes unknown\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [0, 1, 2]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 2, 3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [0, 2]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"EGR1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}